文献速递泌尿生殖与妇科肿瘤放疗

循环中性粒细胞与肿瘤相关髓系细胞可作为局部晚期宫颈癌放化疗反应的强效生物标志物

Circulating neutrophils and tumor-associated myeloid cells function as a powerful biomarker for response to chemoradiation in locally advanced cervical cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2023-01-11

研究纳入两个局部晚期宫颈癌队列(回顾性临床队列与前瞻性转化队列),分析基线及治疗期间血液学参数与疾病结局的相关性,并通过流式细胞术检测循环髓系细胞与肿瘤相关髓系细胞(TSAMs)。结果显示治疗期间平均中性粒细胞绝对计数(mANC)升高与更差的无局部失败生存和总生存相关,TSAMs在放化疗第5周降至最低,循环髓系细胞同期升高,二者呈负相关。

要点

  • 治疗期间平均ANC升高与回顾性队列无局部失败生存更差及前瞻性队列总生存更差相关。
  • mANC与远处转移差异无关。
  • CD11b+CD11c- TSAMs在放化疗第5周降至最低,同期循环髓系细胞升高,二者呈负相关。

核心结论

  • 治疗期间平均中性粒细胞计数可预测疾病相关结局,中性粒细胞可能参与放化疗抵抗,测量瘤内免疫活性具有重要意义。

研究设计与样本

  • 研究纳入两个局部晚期宫颈癌患者队列:一个回顾性临床队列和一个前瞻性转化队列。
  • 回顾性队列在基线及放化疗期间每周采集血液学参数,前瞻性队列在基线及放化疗期间每两周采集,两队列均在首次随访时采集(前瞻性队列平均14.7周,范围8.1-25.1周;回顾性队列5.3周,范围2.7-9.0周)。
  • 分析血小板、血红蛋白、中性粒细胞绝对计数(ANC)和淋巴细胞绝对计数(ALC)的基线值、治疗期间平均值及最低值与疾病结局的相关性。
  • 前瞻性队列通过新型连续细胞刷采样法从肿瘤组织分离TSAMs,从外周血单个核细胞(PBMCs)分离循环髓系细胞,并用流式细胞术分析。

主要发现

  • 在两个队列中,唯一与生存显著相关的血液学参数是治疗期间平均ANC(mANC)升高,分别与回顾性队列无局部失败生存率更低和前瞻性队列总生存率更低相关。
  • mANC与远处转移差异无关。
  • CD11b+CD11c- TSAMs作为瘤内中性粒细胞的替代标志物,在放化疗过程中稳步下降,于治疗第5周降至最低。
  • 相反,从PBMCs中鉴定的循环髓系细胞在治疗第5周内稳步增加。
  • 回归分析证实该时间点循环髓系细胞与TSAMs呈负相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The immune system's role in mediating the cytotoxic effects of chemoradiotherapy remains not completely understood. The integration of immunotherapies into treatment will require insight into features and timing of the immune microenvironment associated with treatment response. Here, we investigated the role of circulating neutrophils and tumor-associated myeloid cells (TSAMs) as potential agents and biomarkers for disease-related outcomes in locally advanced cervical cancer (LACC). MATERIAL AND METHODS: Hematologic parameters for two LACC patient cohorts, a retrospective clinical and a prospective translational cohort, were obtained at baseline, weekly during chemoradiotherapy for the retrospective cohort, biweekly during chemoradiotherapy for the prospective cohort, and at the first follow-up visit for both cohorts (mean 14.7 weeks, range 8.1-25.1 weeks for the prospective cohort and 5.3 weeks with a range of 2.7-9.0 weeks for the retrospective cohort). In both cohorts, baseline as well as mean and lowest on-treatment values for platelets, hemoglobin, absolute neutrophil count (ANC), and absolute lymphocyte count (ALC) were analyzed for correlations with disease-related outcomes. In the prospective cohort, circulating myeloid cells were isolated from peripheral blood mononuclear cells (PBMCs), and TSAMs were isolated from tumor tissue via a novel serial cytobrush sampling assay. The samples were analyzed by flow cytometry. RESULTS: In both cohorts, the only hematologic parameter significantly associated with survival was elevated on-treatment mean ANC (mANC), which was associated with lower local failure-free and overall survival rates in the retrospective and prospective cohorts, respectively. mANC was not associated with a difference in distant metastases. CD11b+CD11c- TSAMs, which act as a surrogate marker for intratumoral neutrophils, steadily decreased during the course of chemoRT and nadier'd at week 5 of treatment. Conversely, circulating myeloid cells identified from PBMCs steadily increased through week 5 of treatment. Regression analysis confirmed an inverse relationship between circulating myeloid cells and TSAMs at this time point. CONCLUSIONS: These findings identify on-treatment mean neutrophil count as a predictor of disease-related outcomes, suggest that neutrophils contribute to chemoradiation treatment resistance, and demonstrate the importance of techniques to measure intratumoral immune activity.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Gjyshi O, Grippin A, Andring L, et al. Circulating neutrophils and tumor-associated myeloid cells function as a powerful biomarker for response to chemoradiation in locally advanced cervical cancer. Clin Transl Radiat Oncol. 2023. PMID: 36935860. doi:10.1016/j.ctro.2023.100578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。